Trial Profile

Safety and eficity of 2.5mg prasugrel therapy in the eldely or low body weight Japanese patients undergoing percutaneous coronary intervention

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Prasugrel (Primary)
Indications Ischaemic heart disorders
Focus Therapeutic Use

Most Recent Events

29 Jun 2018 Primary endpoint (comparison of the prevalence of LPR between the 2.5-mg and 3.75-mg maintenance doses of prasugrel) has been met.
29 Jun 2018 Status changed from recruiting to discontinued.
29 Jun 2018 Results published in the Circulation Journal.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com